Enabling New Therapeutic Pathways by Targeting the Extracellular Matrix
Location: United States, California, Emeryville
Total raised: $55M
Founded date: 2012
Investors 2
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| - | MBC BioLab... | mbcbiolabs... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.05.2017 | Series B | $30M | - |
| 01.12.2015 | Series A | $25M | Lilly Vent... |
Mentions in press and media 9
| Date | Title | Description |
| 29.04.2019 | Daily funding roundup - April 29th, 2019 | Duco raised $1.7M; Specright secured $8.8M; Dyndrite closed $10M; A Cloud Guru landed $33M Duco: Duco is a data engineering technology company that provides self-service data engineering in the cloud. Duco has raised $1.7 million in seed fu... |
| 29.04.2019 | Term Sheet — Monday, April 29 | GROWTH AT ALL COSTS Good morning, Term Sheet readers — I’m back! Paid Content How can you protect what you can't see? From ExtraHop I read a Wall Street Journal column titled, “Why Investors Don’t Care That Snap and Lyft Are Hemorrhaging Mo... |
| 22.05.2017 | Symic Bio Secures $30M Series B Financing | Symic Bio, a San Francisco, CA-based biopharmaceutical company developing novel matrix regulator therapeutics, closed a $30m Series B financing. Backers included all current major investors as well as new investor Heda Ventures. The company... |
| 01.12.2015 | Eli Lilly’s venture arm invests in $25M round for Symic Biomedical | “We’re pretty unique in our approach to this,” Horne said. “It’s equally exciting and challenging.” The company has now raised $43 million since it was founded in 2012. The research comes out of Indiana – Purdue University researcher Dr. Al... |
| 01.12.2015 | Symic Secures $25M in Series A-2 Financing | Symic, a San Francisco, CA-based clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), secured $25m in Series A-2 financing. The round was led by Lilly Ventures with part... |
| 01.12.2015 | Lilly backs a $25M round for anti-inflammatory startup Symic | Symic CEO Ken Horne San Francisco's Symic raised $25 million to fund its work on a pair of anti-inflammatory medicines targeting the extracellular matrix, recruiting Eli Lilly ($LLY) to lead the round as it works through clinical developmen... |
| 01.12.2015 | Daily funding roundup - December 1, 2015 | AppDynamics raised $158M; Symic secured $25M; Deskbookers announced $1.6M funding Deskbookers, an online platform for booking work and meeting spaces, today announced that it has secured $1.6 million in seed funding from Point Nine Capital ... |
| 06.01.2015 | Symic Biomedical Secures $15M in Series A | SAN FRANCISCO, CA, Symic Biomedical announced today that the company has secured $15 million in Series A financing. >> Click here for more funding data on Symic Biomedical >> To export Symic Biomedical funding data to PDF an... |
| - | Eli Lilly’s venture arm invests in $25M round for Symic Biomedical | Bay Area startup Symic Biomedical just closed out a $25 million Series A-2 round, led by Eli Lilly’s venture arm. The company is developing drugs that target the extracellular matrix – focusing on diseases like osteoarthritis. Symic just ki... |